TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04257552

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Beyond Pregnancy
Description: Web-based application grounded in tenants of behavioral economics.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pre-Scheduled Postpartum Visit
Description: Participants will have their postpartum visit scheduled while they are still in the hospital after delivery.
Study: NCT03281369

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin: 80 mg/m\^2 administered by IV infusion on Day 1 of each 21 day cycle. Treatment will be capped after 6 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab: 600 mg administered by IV infusion on Day 1 of every 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab: 600 mg administered by IV infusion on Day 1 of every 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: 5-FU 800 mg/m\^2 administerd by IV infusion on Days 1-5 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: 5-FU 800 mg/m\^2 administerd by IV infusion on Days 1-5 of each 21 day cycle.
Study: NCT03622944

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: spinal stabilization exercise were applied three sessions in a week totally six weeks.
Study: NCT04257552

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Participants will receive texts related to infant care to mirror the attention participants receive in the Healthy Beyond Pregnancy intervention.
Study: NCT00852423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Description: DHA-PQ tablets are green film coated intended for oral use and contain 20/160mg or 40/320mg of dihydroartemisinin (DHA) and piperaquine phosphate (PQ) respectively. In this trial the 40/320mg for adults will be used. Developed by Sigma Tau in partnership with Medicines for Malaria Venture.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate-mefloquine
Description: MQAS will be provided as a fixed-dose ACT. There are 2 strengths (AS25+MQ55mg and AS100+MQ220mg) and dosing regimen is calculated according to 12 mg/kg AS and 24mg/kgMQ total dose over three days. Pregnant women will receive 2 tablets/day for 3 days. It is developed by Farmanguinhos with the Drugs for Neglected Diseases Initiative. To be noted: if the FDCs will not get the WHO pre-qualification before the start of recruitment, the separate AS and MQ will be used

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate-amodiaquine
Description: AQAS, developed by teh DNDi with Sanofi-Aventis and manufactured by Sanofi-Aventis, has been pre-qualified by the WHO in 2008 and is available in several African countries, including those involved in this trial. AQ-AS tablets are round, yellow on one side and white-slightly yellow on the other, with a breaking bar, AS engraved on one side and either 25, 50 or 100 on the other side. Tablets to be used in this trial are those 100mg/270mg AS/AQ, containing 100 mg of artesunate, 352.640 mg of amodiaquine hydrochloride corresponding to 270mg of amodiaquine base.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine
Description: AL (tablets containing a FDC of 20 mg of artemether and 120 mg of lumefantrine) is manufactured by Novartis and has been extensively used in Africa for the treatment of uncomplicated malaria. AL was registered in Switzerland in 1999, has since received marketing authorisation in several endemic and non-endemic countries and it is WHO pre-qualified.
Study: NCT06100107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Therapy exercise
Description: Mirror Therapy for the upper limb involves the use of a mirror to create a reflected image of the unaffected arm, making it appear as if both arms are moving symmetrically. During the therapy, the patient places their affected arm behind the mirror and their unaffected arm in front. While focusing on the mirror reflection, the patient performs various movements with the unaffected arm, giving the illusion that the affected arm is moving normally.
Study: NCT02256189

Intervention type: DRUG
Group type: OTHER
Intervention: Sitagliptin
Description: Sitagliptin 100 mg daily
Study: NCT04012333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLIMEL 7,6%E / PeriOLIMEL 2,5%E
Description: OLIMEL 7,6%E will be administered via a central access whereas PeriOLIMEL 2,5%E will be administered peripherally.
Study: NCT03552289

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cook Advance® Enforcer 35 Focal-Force Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter
Description: The Enforcer balloon device will be used in treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional angioplasty balloon catheters
Description: Commercially available angioplasty balloon devices will be used in treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula
Study: NCT01934868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prolotherapy solution of 20% dextrose
Description: After verifying the anatomy of the lumbosacral spine under ultrasound, a 9cm 22 gauge needle will be used to inject the prolotherapy solution to each of the points specified. In order to view the needle under ultrasound, a needle at least as thick as 22G is required. In order for the prolotherapy injections to be safe, bone must be contacted in order to avoid nerve damage. At each point a total of 1cc prolotherapy solution will be injected.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Steroid Injection
Description: Prior to the epidural injection a local anaesthetic solution of 1% lidocaine will be injected into the relevant subcutaneous and ligamentous interlaminar space. The injectant solution will be comprised of 80mg methylprednisolone combined with 10mg (2cc) 0.5% bupivicaine. The resulting 4cc will be diluted with another 4cc of normal saline giving a total volume of 8cc. A loss of resistance technique will be used and radiocontrast dye will be injected to verify the placement of the needle prior to injecting the steroid solution.
Study: NCT01845519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Email
Description: Participants will receive tailored emails.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Targeted Email
Description: Participants will receive targeted emails.
Study: NCT04296604

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
Study: NCT01769612

Intervention type: OTHER
Intervention: No Intervention
Study: NCT04693806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous CO2 Level
Description: Embryos will be cultured in a single, continuous CO2 setting
Study: NCT04528004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside
Description: Nicotinamide riboside 250mg capsules

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo 250mg capsules
Study: NCT02561676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Program Type 1
Description: The classes will discuss topics related to health and functioning of people with spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about 30 minutes per day that relate to the topics discussed in class.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Program Type 2
Description: The classes will discuss topics related to health and functioning of people with spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about 30 minutes per day that relate to the topics discussed in class.
Study: NCT02443155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0114-0006
Description: NNC0114-0006 12 mg/kg administered i.v (intravenously) every 6 weeks. Subjects will continue their pre-trial insulin treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0114-0006
Description: NNC0114-0006 12 mg/kg administered i.v (intravenously) every 6 weeks. Subjects will continue their pre-trial insulin treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: Liraglutide 1.8 mg administered s.c. (subcutaneously) daily. Subjects will continue their pre-trial insulin treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Liraglutide 1.8 mg administered s.c. (subcutaneously) daily. Subjects will continue their pre-trial insulin treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Placebo administered s.c (subcutaneously) or i.v ( intravenously). Subjects will continue their pre-trial insulin treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo administered s.c (subcutaneously) or i.v ( intravenously). Subjects will continue their pre-trial insulin treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo administered s.c (subcutaneously) or i.v ( intravenously). Subjects will continue their pre-trial insulin treatment
Study: NCT01059890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefotaxime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfocine
Study: NCT04261283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The Circuit Training will be consisting of:~1. Habituation Exercises~2. Exercises for the gaze stability (The two exercises are specifically for the patients who reported a high score on oscillopsia severity questionnaire~3. Exercises to improve Saccade Latency.~4. Adaptation Exercises~5. Substitution Exercises~6. Postural Control Exercises~7. General Conditioning Activities~8. Cawthorne-Cooksey Exercises~9. Ocular Motor Exercises~10. Gait Exercises~11. Treatment to Decrease Sensitivity to Motion in the Environment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Medicines as prescribed by the ear, nose, and throat (ENT) specialist and Home-based exercise Programme (Simple and general vestibular rehabilitation exercises) will be recommended to the patients to perform. ( Not under the supervision of neuro-therapist)
Study: NCT03375762

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote ischemic perconditioning
Description: Five 5-minute inflations/deflations of an automatic device placed on the upper non-paretic arm initiated in the ambulance on the way to hospital in the case of stroke code activation and RACE score \>0 and RACE motor item\>0

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham remote perconditioning
Description: Sham five 5-minute inflations/deflations of an automatic device placed on the upper non-paretic arm initiated in the ambulance on the way to hospital in the case of stroke code activation and RACE score \>0 and RACE motor item\>0
Study: NCT01976624

Intervention type: DRUG
Intervention: bimatoprost/timolol
Description: Bimatoprost/timolol (Ganfort®) treatment for open-angle glaucoma or ocular hypertension as per local standard of care in clinical practice.
Study: NCT05231421

Intervention type: BEHAVIORAL
Intervention: Focus Group
Description: Each focus group will consist of 5-10 participants. They will first introduce to each other and be asked to keep information shared during the session private. The moderator will initiate some questions for the group to discuss. Prompt and follow-up questions will be asked. There is no right or wrong answer for each question and no sensitive questions will be asked. The conversations during the focus group discussion will be recorded. The group will be debriefed about the purpose of the study and have a chance to ask any questions about the study if they have. The focus group discussion for each session will last about 60-90 minutes.
Study: NCT00862394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDP/Formoterol Next DPI
Description: BDP/Formoterol Next DPI 100/6 µg (daily dose : 200/12 µg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foster
Description: BDP/Formoterol HFA pMDI 100/6 µg (daily dose : 200/12 µg)
Study: NCT03281369

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil (5-FU)
Description: 5-FU 800 mg/m\^2 administerd by IV infusion on Days 1-5 of each 21 day cycle.
Study: NCT00862394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDP/Formoterol Next DPI
Description: BDP/Formoterol 100/6 µg (daily dose : 400/24 µg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foster
Description: BDP/Formoterol HFA pMDI 100/6 µg (daily dose : 400/24 µg)
Study: NCT04001660

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subbrow Blepharoplasty Combined with Double Eyelid Surgery
Description: An upper incision is made along the inferior margin of the eyebrow. A lower incision is determined according to necessary amount of skin excision. Then the skin and subcutaneous tissue were excised. The orbicularis oculi muscle (OOM) was separated and an OOM flap dissection was extended to the width of 15mm. A dissected OOM flap was lifted up and three transverse 3-0 nylon sutures were placed to fix it to the periosteum and then covered by the upper myocutaneous flap of the supraorbital rim. Through eyelid-crease approach the supratarsal upper eyelid skin and orbital fat was excised, adjusted and reshaped double-fold eyelids at the same time.
Study: NCT04292379

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard procedures and assessments

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care Bundle
Description: Suicide risk screening tool, mental health assessment tool, follow-up appointment
Study: NCT03611036

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Upper limbs Strength training; done with dumbbells whose weight corresponds to 60-80% of the maximal voluntary force in abduction measured initially, during 4 weeks
Study: NCT02628704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: The fixed dose of selinexor is 60 mg (three 20 mg tablets)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for selinexor)
Description: sugar tablet manufactured to mimic selinexor tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carfilzomib
Description: Administered as an IV infusion on Days 1, 2, 8, 9, 15 and 16 of each 4-week cycle for Cycles 1-13 and then on Days 1, 2, 15, and 16 for Cycles ≥ 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib
Description: Administered as an IV infusion on Days 1, 2, 8, 9, 15 and 16 of each 4-week cycle for Cycles 1-13 and then on Days 1, 2, 15, and 16 for Cycles ≥ 14.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Fixed oral dose of 20 mg will be given twice weekly (Days 1, 2, 8, 9, 15, 16, 22 and 23) in each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Fixed oral dose of 20 mg will be given twice weekly (Days 1, 2, 8, 9, 15, 16, 22 and 23) in each cycle.
Study: NCT02031627

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pneumatic compression - 1 hour per day
Description: Pneumatic compression treatment once per day (1 hour)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pneumatic compression - 2 hours per day
Description: pneumatic compression treatment twice per day in the AM \& PM (2 hours)
Study: NCT03611036

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endurance training
Description: Upper limbs Endurance training of the ; done with dumbbells whose weight corresponds to 30% of the maximum voluntary force in abduction measured initially, during 4 weeks
Study: NCT04494360

Intervention type: OTHER
Intervention: No intervention
Description: No investigational medicinal product will be administered as a part of this study.
Study: NCT02031627

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pneumatic compression - 4 hours per day
Description: pneumatic compression treatment twice per day consisting of 2 consecutive 1 hour treatments in the AM \& PM (4 hours)
Study: NCT03300427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sacubitril/valsatran
Description: sacubitril/valsatran 100 or 200 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan
Description: Valsartan 80 or 160 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to valsartan
Description: placebo to valsartan 80 or 160 BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to sacubitril/valsartan
Description: placebo to sacubitril/valsartan 100 or 200 mg BID
Study: NCT03641521

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-led behavioral strategies
Description: Intervention parents participated in an additional 20-25-min segment led by the nutrition educator during which the week's behavioral strategy was introduced. The following six behavioral strategies were introduced (one each week) as a segment of each cooking skills session: 1) have your child help prepare vegetables for meals (Child Help), 2) use a plate that shows the amount of vegetables to include for a meal (My Plate), 3) make vegetables visible and accessible by removing other foods from the dining area during the meal and leaving the vegetables (Make Avail/Visible), 4) serve at least 2 vegetables with the meal (Serve 2), 5) serve vegetables before the meal (Serve First), and 6) use a bigger spoon to serve the vegetables (Big Spoon).
Study: NCT00223652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone cognitive behavioral therapy
Description: An initial treatment phase consisting of 12 weekly sessions aimed at reducing symptoms of depression, and a booster phase in which 4 sessions are provided at increasingly greater intervals to target maintenance of treatment gains.
Study: NCT00441012

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Modified Process Vaccine
Description: Modified process vaccine HBsAg 5 ug/0.5 mL and PRP \[OMPC\] 7.5 ug/0.5 mL in a 3-dose regimen at 2, 4 \& 12 months of age. Duration of treatment is 11 months.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: COMVAX™
Description: COMVAX™ HBsAg 5 ug/0.5 mL and PRP \[OMPC\] 7.5 ug/0.5 mL in a 3-dose regimen at 2, 4, and 12 months of age. Duration of treatment is 11 months.
Study: NCT00559013

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Staple line reinforcement
Description: Placement of reinforcement material on circular anastomotic staple line for prevention of leak during and post surgery.
Study: NCT02929368

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICC implantation under fluoroscopy
Description: PICC Catheter implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICC Implantation under Sherlock System
Description: PICC Catheter implantation
Study: NCT02727881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Squalamine lactate ophthalmic solution, 0.2%
Description: Squalamine lactate ophthalmic solution, 0.2%
Study: NCT03557736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training mode
Description: type of exercise training completed for 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training mode
Description: type of exercise training completed for 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training mode
Description: type of exercise training completed for 12 weeks
Study: NCT00926991

Intervention type: OTHER
Intervention: No intervention
Description: No intervention; observation only
Study: NCT01432704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: colecalciferol
Description: Once weekly peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) that contain 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D3 for a duration of 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: colecalciferol
Description: Once weekly peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) that contain 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D3 for a duration of 12 months
Study: NCT02977039

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NDPR diet
Description: nutrient rich plant based diert

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: USDA healthy eating diet
Description: DASH diet
Study: NCT01838655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone
Description: Oral dose of 2mg daily for 12 months.
Study: NCT02027064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-alpha